Site Search

Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance

Investment will support discovery research of a novel Gene Coding^TM approach that could benefit all people with CF regardless of their mutation
 

Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.

The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.

New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease